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Effects of adolescence-onset hypogonadism on 
metabolism, bone mineral density and quality 
of life in adulthood
Abstract: In a cross-sectional study of 54 patients with 
adolescence-onset hypogonadism (33 females, 21 males; 
age range: 19–40 years), medical care, quality of life, and 
health status were assessed. Most patients had received 
adequate medical care with short cumulative periods of 
interruption of hormone replacement. The prevalence of 
the metabolic syndrome was 27% in females and 19% in 
males. In comparison to the general population, females 
had both a lower bone mineral density (dual-energy X-ray 
absorptiometry, Z-score = −0.8, p < 0.001) and a higher prev-
alence of obesity (age 19–29 years: study population 35%, 
general population 4%). The body fat percentage (dual-
energy X-ray absorptiometry) was significantly elevated 
(age 19–29 years: females Z-score = +1.8, p < 0.001, males 
Z-score = +2.4, p = 0.001). Quality of life (SF-36) was normal. 
Despite adequate treatment, patients with early-onset 
hypogonadism are prone to develop signs and symptoms 
consistent with inadequate hormone replacement. A suc-
cessful transition from pediatric to adult medicine seems 
important to optimize treatment outcomes.
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Introduction
Hypogonadotropic hypogonadism is caused by abnor-
malities within the pituitary gland or the hypothalamus, 
whereas primary gonadal failure results in hypergonado-
tropic hypogonadism (1). A long-term substitution of sex 
hormones is essential for both male (1, 2) and female (1, 
3) patients to prevent health problems associated with sex 
hormone deficiency. These include the reduction of bone 
mineral density (4, 5) and the development of a metabolic 
syndrome in men (6) or some of its components, such as 
dyslipidemia or an increase in central fat in women (7). 
Non-adherence or insufficient medical care have been 
observed for women with Turner syndrome (8–10), pos-
sibly contributing to the abovementioned health prob-
lems. Similar health issues have been reported for the 
Klinefelter syndrome. However, very few studies have 
been conducted to analyze the long-term consequences of 
adolescence-onset hypogonadism of diverse origins. The 
objectives of our study were to evaluate endocrine, met-
abolic, and skeletal parameters and to assess quality of 
life in patients with hypogonadism of various causes that 
manifested in adolescence.
Materials and methods
This clinical cross-sectional study was conducted at the Univer-
sity Hospital Dresden, Dresden, Germany. Inclusion criteria for 
study participation were manifestation of hypogonadism at the age 
of  < 18  years and the presence of hypogonadism at the time of re-
examination in adulthood. Exclusion criteria were severe chronic 
diseases. Figure 1 shows the participant flow.
Fifty-four Caucasian patients (33 females, 21 males; age range: 
19–40 years) with hypogonadism of mixed etiology (Table 1) were 
included in the analysis. Informed, written consent was obtained 
from all participating patients. The study was approved by the Ethics 
Committee of the Dresden University of Technology (EK 66022010) 
and was conducted in accordance with the Declaration of Helsinki.
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A standardized medical history was obtained from patient 
files, as well as an interview and correspondence with the attending 
physician to collect information on past and present medical care, 
including age at initiation of sex hormone substitution and adher-
ence to hormone replacement therapy (HRT). A physical examination 
including the measurement of height, weight, waist circumference, 
and blood pressure was performed. A fasting blood sample was col-
lected to measure sex hormones and parameters of lipid and glucose 
metabolism. For all study participants, a dual-energy X-ray absorpti-
ometry (DXA) using the Lunar ProdigyTM device (GE Medical Systems, 
Madison, WI, USA) was performed. Bone mineral density (BMD) was 
measured at the lumbar spine (L1 to L4), both femoral necks and 
both total hips and Z- and T-scores were provided by the DXA soft-
ware based on a reference population. Measurements were evaluated 
according to the positions of the International Society for Clinical 
Densitometry (11). Osteopenia and osteoporosis were defined accord-




Did not show up for or
cancelled appointment (n=4)
Could not be contacted (n=3)
Deceased (n=3)
Participated in study (n=56)
Study performed as specified in protocol (n=56)
Included in data analysis (n=54)
Excluded from data analysis (no hypogonadism at
the time of the study) (n=2)
Patients evaluated for potential enrolment (n=105)
Figure 1: Study enrolment diagram.
Table 1: Characteristics of the study population.
  Male patients (n = 21)  Female patients (n = 33)
Age (years), mean±standard deviation   27.1±6.3  25.6±4.8
Hypergonadotropic hypogonadism, n (%)   9 (42.9)  27 (81.8)
Ullrich-Turner syndrome, n (%)   –  26 (78.8)
Klinefelter syndrome, n (%)   6 (28.6)  –
Gonadectomy, n (%)   2 (9.5)  1 (3.0)
Others, n (%)   1 (4.8)  –
Hypogonadotropic hypogonadism, n (%)   12 (57.1)  6 (18.2)
Status post brain tumor, n (%)   4 (19.0)  3 (9.1)
Multiple pituitary hormone deficiency, n (%)  4 (19.0)  –
Kallmann syndrome, n (%)   1 (4.8)  1 (3.0)
Prader-Willi syndrome, n (%)   –  1 (3.0)
Others, n (%)   3 (14.3)  1 (3.0)
osteoporosis was diagnosed when the lowest T-score was lower than 
−2.5 and osteopenia when the lowest T-score was lower than −1.0 but 
equal to or  > −2.5 (4). The body mass index (BMI) was calculated and 
every patient was assigned to a weight category based on the WHO 
classification (12). Weight class frequency distributions based on 
data collected through the Telephone Health Survey 2003 allowed a 
comparison with the German general population (13). A Z-score for 
each measurement of body fat percentage was based on the refer-
ence population derived from the DXA software. For diagnosis of a 
metabolic syndrome, the joint definition of multiple organizations, 
for example the American Heart Association, from 2009 was applied 
(14). The prevalence of the metabolic syndrome in our study popula-
tion was compared to that of the general population using data col-
lected in a Germany-wide cross-sectional study (15). Health-related 
quality of life (QoL) was assessed using the SF-36 Health Survey. The 
data were analyzed following the instructions of the appropriate 
manual and compared to the norm sample from 1994 (16).
All statistical analyses were performed with IBM SPSS Statistics 
for Windows Version 19.0 and 22.0 (IBM Corp., Armonk, NY, USA). 
To test for normal distribution, the Kolmogorov-Smirnov test or the 
Shapiro-Wilks test were used. For comparisons of the study popula-
tion and the general population, a one-sample t-test was employed 
for samples with normal distribution and a Wilcoxon test for samples 
with no normal distribution. To compare two normally distributed 
groups, a t-test for independent samples was applied. For samples 
that were not normally distributed, a Mann-Whitney U-test was used. 
For comparisons of frequency distributions in the study population 
and the general population, a χ2-test was performed. The level of sig-
nificance was set to p-value = 0.05 in all analyses.
Results
Medical care
Out of 54 patients, 48 (89%) had been treated in the 
Department of Pediatric Endocrinology of the University 
Hospital Dresden for hypogonadism in their youth. Five 
patients (9%) had not received medical care concerning 
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hypogonadism in childhood or adolescence. More than 
80% of the study participants had experienced either 
a spontaneous or sex-hormone-induced puberty before 
their 16th birthday. One male patient with Kallmann syn-
drome had remained without hormonal replacement until 
the age of 25 years. In 82% of the female patients and 48% 
of the male patients, puberty had to be initiated by HRT.
At the time of the study, all male patients and 88% of 
the female patients were receiving HRT. In males, testos-
terone replacement therapy was performed using intra-
muscular injection of testosterone undecanoate (n = 11), 
intramuscular injection of testosterone enanthate (n = 4), or 
transdermal testosterone gel (n = 6). The medical treatment 
concerning hypogonadism in male study participants was 
provided by an adult endocrinologist in 62%. Twenty-four 
percent were in urological care and 10% were under the 
care of their general practitioner. In females, diverse thera-
peutic regimens of HRT with equine or synthetic estrogens 
variably combined with progestogens were applied. Sixty-
four percent were treated by a gynecologist and 21% by an 
endocrinologist. One woman was treated by a general prac-
titioner. Twelve percent of the female patients did not cur-
rently receive any medical care concerning hypogonadism.
The average cumulative period of interruption of 
HRT amounted to 0.4  years (SD = 0.8) for male patients 
and 1.3  years (SD = 3.3) for female patients. Seventy-one 
percent of the male and 67% of the female study partici-
pants had not had any relevant interruptions of HRT. The 
longest period of interruption in the male study popula-
tion was 3.0 years, whereas 15% percent of the female 
patients discontinued HRT for more than 3 years. Of these, 
two women (6%) interrupted HRT for more than 10 years.
Bone mineral density
The female patients had a significantly lower mean BMD 
at lumbar spine and total hip than the female reference 
population of the same age (Table 2). Nineteen female 
study participants (58%) were diagnosed with osteopenia 
and one (3%) with osteoporosis. The average BMD of male 
patients was not significantly decreased in comparison 
with the control group for both lumbar spine and total hip 
(Table 2). Seven male patients (33%) had osteopenia and 
two men (10%) had osteoporosis.
BMI
On average, female study participants were pre-obese 
while male study participants exhibited a mean BMI in 
the normal range. For both men and women, only slight 
differences between the age groups 19–29  years and 
30–40 years were found (Table 2).
Figure 2 illustrates the prevalence of the WHO BMI 
categories in the study population in comparison to the 
German general population (13) for the different age 
groups and genders. Female study participants had 
a higher prevalence of obesity when compared to the 
German general female population for both age groups. 
Table 2: Bone mineral density and body composition (mean±standard deviation). Comparison of study population with reference 
population.
  Male patients 
(age 19−29 years: n = 14; 
age 30−40 years: n = 7)
  p-Value  Female patients 
(age 19−29 years: n = 23; 
age 30−40 years: n = 10)
  p-Value
BMD lumbar spine   1.162±0.209    1.086±0.123 
 Z-score   −0.3±1.5  0.343  −0.8±1.0   < 0.001a
 T-score   −0.5±1.7    −0.7±1.1 
BMD total hip   1.042±0.214    0.929±0.132 
 Z-score   −0.3±1.4  0.317  −0.7±0.9   < 0.001a
 T-score   −0.4±1.6    −0.6±1.1 
BMI, kg/m2
 Age: 19−29 years   24.8±6.6    28.8±7.2 
 Age: 30−40 years   23.4±2.5    27.7±5.8 
Body fat percentage
 Age: 19−29 years   27.3±10.6    42.4±10.2 
  Z-score   2.4±2.1  0.001a  1.8±1.3   < 0.001a
 Age: 30−40 years   24.6±10.7    38.5±10.6 
  Z-score   1.0±2.4  0.309  1.1±1.3  0.028a
aSignificant. For statistical analyses of BMD measurements at the total hip, the mean of the two bone mineral densities, Z-scores and 
T-scores were used for each patient. BMD, bone mineral density; BMI, body mass index.
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Male patients aged 19−29  years had a higher prevalence 
of both underweight and obesity compared to the age-
matched general male population. The increase of over-
weight and obesity that is observed with increasing age in 
the general male population was not found for our male 
study population.
Body fat percentage
Female study participants of both age groups, in particular 
the younger patients, had a significantly higher mean body 
fat proportion than the female reference population of the 
same age (Table 2). Male patients between 19 and 29 years 
of age also had a significantly higher body fat percentage 
than the age-matched reference population. The body fat in 
the male study participants aged 30–40 years was higher, 
although not significantly, than in the male reference popu-
lation but lower than in the younger male study population.
Metabolic syndrome
The criteria for the diagnosis of a metabolic syndrome 
were met by 27% of the female and 19% of the male study 
participants. In comparison with the German general 
population (15), the prevalence of the metabolic syn-
drome was higher for both female and male patients of 
both age groups (Table 3). However, the observed dif-
ferences between the study and the general population 
were significant only for women of the younger age group 
that exhibited the highest prevalence of the metabolic 
syndrome.
Quality of life
Thirty-two female and all 21 male study participants filled 
out the SF-36 questionnaire. For the summary scores, 
Males, younger age group
Males, older age group
Females, younger age group































































































































Study participants General population
Underweight (BMI <18.50 kg/m²) Normal range (BMI: 18.50 –24.99 kg/m²)
Pre-Obese (BMI: 25.00 –29.99 kg/m²) Obese (BMI ≥ 30.00 kg/m²)
. 
Figure 2: Weight distribution in the study population and in the German general population (13). (A) Male study population aged 
19−29 years (n = 14) and male general population aged 18−29 years. (B) Female study population aged 19−29 years (n = 23) and female 
general population aged 18−29 years. (C) Male study population aged 30−40 years (n = 7) and male general population aged 30−44 years. 
(D) Female study population aged 30−36 years (n = 10) and female general population aged 30−44 years. Blank: underweight [body mass 
index (BMI):  < 18.50 kg/m2]. Dotted: normal range (BMI: 18.50–24.99 kg/m2). Hatched: pre-obese (BMI: 25.00–29.99 kg/m2). Filled: obese 
(BMI:  ≥ 30.00 kg/m2).
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male and female study participants of both age groups 
showed only slight differences from the general popula-
tion (Table 4). However, female study participants aged 
19–30 years had significantly higher mean scores for the 
“physical component summary score” and the domains 
“social functioning” and “bodily pain” but a significantly 
lower score in the domain “physical functioning” than the 
general population. Male study participants between 19 
and 30 years of age had significantly lower scores than the 
general population in the domains “role physical”, “vital-
ity” and “physical functioning”. For the older male and 
female study participants, no significant differences to 
the normal population could be observed for any of the 
domains.
Some of the study participants had psychiatric comor-
bidities that may have affected their QoL. A male study par-
ticipant was treated for schizophrenia with two atypical 
neuroleptics and a selective serotonin reuptake inhibitor 
(SSRI). One patient had been receiving methylphenidate 
for 15  years. Two female patients were treated with an 
atypical neuroleptic and a SSRI, one for obsessive com-
pulsive disorder and the other after a depressive episode 
Table 3: Prevalence of the metabolic syndrome. Comparison of study population with German general population (15).
  Study participants 
age: 19−29 years 




  p-Value  Study participants 
age: 30−40 years 






 Metabolic syndrome, n (%)  2 (14.3%)  6.0%  0.192  2 (28.6%)  14.5%  0.290
Females
 Metabolic syndrome, n (%)  7 (30.4%)  4.2%   < 0.001a  2 (20.0%)  8.6%  0.199
aSignificant.
Table 4: SF-36 results (mean±standard deviation). Comparison of study population with German general population (16).
















 Physical component summary score   51.72± 9.37  50.21±10.24  0.551  50.31±7.29  54.13±6.80  0.256
 Mental component summary score   49.37±6.46  51.54±8.14  0.231  51.32±8.04  50.91±7.75  0.905
 Physical functioning   92.00±11.15  96.21±10.19  0.011a  95.00±7.75  96.44±9.97  0.750
 Role physical   76.67±34.68  95.82±17.56  0.027a  75.00±31.62  91.43±26.27  0.259
 Bodily pain   87.27±25.12  88.91±21.62  0.068  85.50±24.51  89.64±20.42  0.914
 General health   67.86±19.53  77.12±18.33  0.099  58.67±29.94  76.54±16.13  0.204
 Vitality   57.67±13.21  67.52±18.80  0.012a  63.33±24.01  68.53±15.00  0.619
 Social functioning   86.67±24.31  93.12±17.04  0.066  89.58±16.62  92.10±16.38  0.914
 Role emotional   95.56±11.73  94.46±19.51  0.157  83.33±27.89  93.57±23.35  0.914
 Mental health   71.47±19.00  76.49±16.58  0.323  79.33±15.68  77.06±16.44  0.737
Females
 Physical component summary score   55.16±7.17  50.21±10.24  0.022a  52.24±4.98  54.13±6.80  0.354
 Mental component summary score   50.04±6.06  51.54±8.14  0.237  50.74±8.59  50.91±7.75  1.000
 Physical functioning   92.92±10.83  93.95±12.89  0.001a  93.57±4.76  91.03±16.86  0.207
 Role physical   92.00±22.50  87.75±28.57  0.066  100.00±0.00  88.99±22.45  1.000
 Bodily pain   89.60±22.97  83.97±26.57  0.043a  85.29±20.76  84.33±21.23  0.109
 General health   74.60±20.36  74.49±17.65  0.979  62.43±26.36  72.12±15.39  0.368
 Vitality   60.60±18.95  62.21±17.95  0.675  64.29±16.69  63.06±15.79  0.852
 Social functioning   92.00±15.68  89.14±18.34  0.026a  73.21±29.25  87.24±17.37  0.252
 Role emotional   92.00±24.11  91.29±22.48  0.109  100.00±0.00  89.26±23.74  1.000
 Mental health   69.76±14.47  71.75±16.89  0.580  78.86±17.85  71.81±14.03  0.343
aSignificant.
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and periods of increased irritability. Another female study 
participant with a somatization disorder received a SSRI.
Discussion
We performed a cross-sectional study in a cohort of young 
adults with hypogonadism with disease-onset during 
adolescence assessing physical, mental and social health 
status, and QoL. The transition of patients with chronic 
illnesses from pediatric to adult medicine can be prone 
to obstacles that may lead to the patients dropping out 
of medical care (17). For example, patients with Turner 
syndrome are often adequately treated during childhood 
but do not receive satisfactory medical care in adulthood 
(8–10). In our study population, most patients had expe-
rienced a successful transition from pediatric to adult 
health care and the medical care situation of our study 
population was satisfactory. The majority of patients were 
treated by specialists with particular expertise in HRT 
such as endocrinologists or gynecologists. All male and 
most of the female patients were receiving HRT at the time 
of the study. Approximately 70% of the study participants 
had never experienced any relevant interruptions of HRT. 
We observed a clear gender difference in the length of HRT 
interruption in patients who had discontinued therapy, 
with male patients having far shorter interruptions than 
female patients. A possible explanation for this observa-
tion could be the unpleasant symptoms that male patients 
experienced in times of therapy discontinuation including 
loss of libido, increased fatigue, and depressive mood. In 
contrast, most female patients did not report any negative 
symptoms when discontinuing their treatment and some 
reported regular menstrual bleeding and weight gain as 
disadvantages of HRT.
One major result of our study is that gain in body 
weight could not be prevented in female patients with 
hypogonadism receiving HRT. In the female study popu-
lation, the prevalence of obesity and the body fat per-
centage were considerably higher than in the general 
population. In women, no causal link between estrogen 
deficiency and increase of body fat percentage has been 
proven. However, there is data suggesting that a post-
menopausal estrogen deficiency may be associated with 
an increase in body fat (18). Women with Turner syn-
drome have been observed to be more obese in compari-
son to women with normal karyotype (19). Both estrogen 
deficiency and the large proportion of women with 
Turner syndrome in our study population could be seen 
as possible explanations for the considerable prevalence 
of obesity and the high body fat percentage in our female 
study population.
Our male study participants exhibited a weight distri-
bution that differed from that of the general population. In 
the age group 19–29 years, male patients had a higher prev-
alence of both obesity and underweight than the general 
population. The body fat percentage of the younger male 
patients was significantly elevated. It has been found that 
there is a significant inverse correlation between total tes-
tosterone blood concentration and obesity (6). In a study 
on men with prostate cancer undergoing androgen depri-
vation, a significant increase in percentage fat body mass 
and a significant reduction in percentage lean body mass 
were observed (20). Bojesen et  al. found that Klinefelter 
patients without testosterone replacement therapy had a 
significantly higher body mass index and a significantly 
higher body fat percentage than a control group of men 
without Klinefelter syndrome (21). Testosterone deficiency 
is therefore a possible explanation for the high prevalence 
of obesity and increased body fat percentage in our male 
study participants.
In addition, we observed a much higher prevalence 
of the metabolic syndrome in our study population than 
in the German general population. This finding was sta-
tistically significant only in the group of female patients 
aged 19–29. However, a clinical relevance of this result for 
male and older patients seems likely. Low testosterone 
blood concentration can be considered a risk factor for 
metabolic syndrome in men (6). A study on 71 Klinefel-
ter patients showed a greatly increased prevalence of the 
metabolic syndrome in this cohort (21). In women, it has 
been observed that different components of the metabolic 
syndrome, for example, central obesity and dyslipidemia, 
emerge with estrogen deficiency during menopause (7). 
However, the magnitude of the impact of estrogen defi-
ciency independent of other factors, for example, aging, 
on these changes has not been conclusively clarified (7, 
18). For both our male and female study participants, sex 
hormone deficiency could be a possible explanation for 
the highly elevated prevalence of the metabolic syndrome. 
In our female study population, the large proportion of 
patients with Turner syndrome could account for the high 
prevalence of the metabolic syndrome in our study popu-
lation. Patients with Turner syndrome exhibit an elevated 
prevalence of multiple components of the metabolic syn-
drome (22, 23). They have a considerably increased risk 
of developing hypertension, impaired glucose tolerance, 
and type 2 diabetes mellitus (22). The increased frequency 
of hypertriglyceridemia in women with Turner syndrome 
may be a direct consequence of obesity and hyperinsu-
linemia (22).
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Another major result of our study is the reduction of 
bone mineral density, especially in our female study pop-
ulation despite HRT. We found a significantly lower BMD 
in our female study population compared to the reference 
population. The prevalence of osteopenia as a possible 
preliminary stage of osteoporosis was high. Estrogen defi-
ciency has been shown to play an important role in the 
development of osteoporosis as estrogen seems to have 
both anti-catabolic and anabolic effects on bone (24). On 
the general population level, women after menopause 
are mainly affected by osteoporosis. However, it has been 
shown that young women with estrogen deficiency have 
an increased risk for lower bone mineral density and that 
the period without HRT is significantly related to lower 
bone mineral density in these women (25). As four female 
patients were not receiving HRT at the time of the study 
and some patients had long interruptions of HRT, estro-
gen deficiency had likely been an important factor for 
the development of the observed decreased bone mineral 
density. It has been reported that women with Turner syn-
drome are at higher risk of developing osteoporosis (22). 
An intrinsic bone defect is probable as HRT improves but 
does not normalize bone mass. The reduction of bone mass 
is likely caused by a combination of this intrinsic bone 
defect and estrogen deficiency (22). Furthermore, small 
bone size and short height could be confounding factors 
in the measurement of areal bone density in women with 
Turner syndrome (26), possibly leading to overestimation 
of the bone mineral density reduction. As the majority of 
our female study participants were women with Turner 
syndrome, these factors could have contributed to the low 
average BMD observed in the female study population.
In the male study population, decrease of BMD was 
not significant. Compared to the female study population, 
statistical scattering of BMD was higher in the male study 
population, which could be explained by its higher etio-
logical diversity. The substantial prevalence of osteopenia 
and osteoporosis indicates a clinical relevance of the bone 
mass reduction in our male patients. Hypogonadism is a 
common secondary cause of osteoporosis in men (4, 5). 
The influence of testosterone on the male skeleton is partly 
exerted indirectly through estrogen formed by aromatiza-
tion of testosterone (4, 5). Thus, possible explanations for 
the decrease in BMD in our male study participants could 
be a testosterone deficit due to interruptions or delayed 
beginning of HRT as well as insufficient sex hormone 
levels under HRT.
Surprisingly, both female and male study participants 
did not show significant differences in QoL compared 
to the general population, as depicted in the compo-
nent summary scores of the SF-36. Male patients aged 
19−30 years had significantly lower QoL concerning only 
some domains of the questionnaire. However, female 
patients between 19 and 30  years of age showed even 
better QoL concerning certain domains such as “social 
functioning” than the general population. Bannink et al. 
found that young women with Turner syndrome after 
induced puberty and growth hormone therapy had a 
normal health-related QoL and scored higher in some of 
the domains of the SF-36, including “social functioning” 
and “bodily pain” (27). These findings are consistent with 
our results, considering that the majority of the female 
study population were women with Turner syndrome. 
Boman et al. also observed a normal psychological well-
being and self-rated health but more self-reported social 
isolation in these patients (28) and other studies found 
poorer QoL concerning some domains of the SF-36 in 
women with Turner syndrome (29, 30). It is difficult to 
compare our results concerning the male patients to other 
findings because of the heterogeneity of our male study 
population. In an Australian study on 87 men with Kline-
felter syndrome, noticeably poorer outcomes than in the 
general male population have been shown for all evalu-
ated aspects of QoL including self-esteem, body image, 
and subjective well-being (31). Physical characteristics 
and difficulties in academic performance due to learning 
disabilities can lead to low self-esteem and withdrawal 
from peers in adolescents with Klinefelter syndrome (32). 
In a study on 25 children and adults with childhood crani-
opharyngeoma, patients rated their health-related QoL 
considerably lower than healthy controls, especially in 
the domains social and emotional functioning (33). In a 
larger prospective study, it was observed that the degree 
of hypothalamic surgical lesions had a negative impact on 
health-related QoL (34).
Our study had potential limitations. The recruitment 
of the patients may have led to a selection bias. Blood pres-
sure could only be measured once for each patient due to 
organizational reasons. Even though the definition of the 
metabolic syndrome does not explicitly call for a repeated 
measurement, we would recommend it for a more reliable 
diagnosis. As our male study population in particular was 
heterogeneous regarding the cause of hypogonadism, 
comparisons of our results with previous findings may not 
be fully possible. Conversely, our study cohort reflects the 
diversity of patients referred to a pediatric endocrine out-
patient clinic.
In conclusion, our study shows that patients with 
hypogonadism were prone to developing multiple 
health risks typically associated with sex hormone defi-
ciency, even though most of the study participants had 
received satisfactory medical care and HRT. We found a 
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discrepancy between an objectively alarming health situa-
tion and a subjectively normal self-reported QoL. It seems 
as if the health issues found in this study have no or little 
influence on QoL at the relatively young age of our study 
participants. However, there is a high risk for substantial 
future health problems. Whether our findings can be gen-
eralized to all patients with early-onset hypogonadism is 
uncertain. Large-scale prospective studies are needed to 
evaluate different diagnostic and therapeutic regimens for 
patients with hypogonadism with onset in adolescence in 
order to improve long-term health.
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